19545 Visiopharm and Agilent partner to accelerate precision medicine with AI-driven precision pathology solutions for pharma 

Visiopharm, a leading provider of AI-driven precision pathology software for research and diagnostics, and Agilent Technologies Inc., a world leader in life sciences, diagnostics, and applied chemical markets, have announced a strategic partnership to provide pharma with advanced and comprehensive solutions to support the acceleration of precision medicine. 

Breakthroughs in immuno-oncology are revolutionizing cancer care with new and promising targeted treatments. That has created a need for robust and reliable patient selection for clinical trials, bringing targeted treatments to market, and optimal treatment decisions. Tissue biomarkers provide valuable spatially resolved information about protein expression in the tumor micro-environment. 

AI-driven precision pathology has the potential to play a crucial role in developing powerful new predictive assays. It provides a powerful tool for discovery of new biomarkers through the analysis of multiplexed image data, developing investigational devices for clinical trials, and developing scoring principles for novel tissue biomarkers. Moreover, it can aid in the development of image analysis for standardized and automated reading of increasingly complex biomarkers. AI-driven precision pathology from Visiopharm can also be used for measuring and managing staining consistency, which is often vital for both clinical trials and decentralized deployment of new predictive assays. 

The Visiopharm-Agilent partnership will provide a toolbox for AI-driven precision pathology, enabling Pharma to accelerate clinical development by improving patient selection in clinical testing and ultimately supporting diagnostic applications through AI-driven, standardized decision support  biomarker expression. The partnership also provides solutions for monitoring staining consistency in clinical development and clinical practice, further supporting biomarker standardization. 

Michael Grunkin, CEO, Visiopharm, said: “We are excited to strengthen our strategic collaboration with Agilent to accelerate the development of new drug-diagnostic assays. This global collaboration will allow us to support an increasingly important precision medicine agenda.” 

Paul Beresford, VP/GM, Companion Diagnostics, Agilent, said: “We’re thrilled to partner with Visiopharm in providing advanced digital pathology and AI-based solutions to accelerate biomarker discovery and clinical development. Together, we are committed to enabling pharma to bring innovative and tailored treatments to patients faster, ultimately advancing precision medicine.” 

The partnership expands upon the existing relationship between Visiopharm and Agilent, who have been collaborating on the development of several quantitative IVD APPs and announced a worldwide distribution agreement. 

About Visiopharm

Visiopharm® is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no less than eight diagnostic algorithms cleared under IVDR for EU customers. These applications provide diagnostic decision support and and can be easily activated and integrated into existing lab workflows.

Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with offices in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.


Johanne Louise Brændgaard
Chief Marketing Officer

Categories: Press Releases
Your message has been successfully sent!